Source: FierceBiotech AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson & Johnson’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year. Risankizumab aced all the primary and ranked secondary endpoints across three clinical trials, two…...